GÃ©rard Zalcman

List of Publications by Year
in descending order

153	18,355	53939 47	14779 131
papers	citations	h-index	g-index

173	173	173	24259
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. Journal of Thoracic Oncology, 2022, 17, 239-251.	0.5	51
2	Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. European Journal of Cancer, 2022, 162, 182-193.	1.3	40
3	Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial. Journal of Clinical Oncology, 2022, 40, 719-728.	0.8	37
4	Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 104-114.	5.1	123
5	SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents. JAMA Oncology, 2022, 8, 612.	3.4	35
6	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature Medicine, 2022, 28, 315-324.	15.2	225
7	Measuring Walking Speed Failed to Predict Early Death and Toxicity in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) Selected for Undergoing First-Line Systemic Treatment: An Observational Exploratory Study. Cancers, 2022, 14, 1344.	1.7	3
8	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer, 2022, 167, 8-16.	0.9	9
9	The Use of Pro-Angiogenic and/or Pro-Hypoxic miRNAs as Tools to Monitor Patients with Diffuse Gliomas. International Journal of Molecular Sciences, 2022, 23, 6042.	1.8	1
10	Systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of patients with cancer treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2022, 40, 2585-2585.	0.8	0
11	Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentreÂreal-life cohort study. European Journal of Cancer, 2022, 173, 33-40.	1.3	5
12	The STK38â€“XPO1 axis, a new actor in physiology and cancer. Cellular and Molecular Life Sciences, 2021, 78, 1943-1955.	2.4	8
13	In vitro bone metastasis dwelling in a 3D bioengineered niche. Biomaterials, 2021, 269, 120624.	5.7	17
14	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet, The, 2021, 397, 375-386.	6.3	638
15	Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms. Cancers, 2021, 13, 643.	1.7	19
16	Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. European Journal of Cancer, 2021, 145, 179-182.	1.3	9
17	Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients. Cancers, 2021, 13, 1040.	1.7	13
18	Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. Rheumatology, 2021, 60, 5753-5764.	0.9	17

#	Article	IF	Citations
19	National early access programs and clinical trials: What opportunities for early access to therapeutic innovations for patients with malignant melanoma?. Cancer, 2021, 127, 2181-2183.	2.0	2
20	Intergroupe francophone de cancÃ©rologie thoracique, SociÃ©tÃ© de pneumologie de langue franÃ§aise, and SociÃ©tÃ© dâ€™imagerie thoracique statement paper on lung cancer screening. Diagnostic and Interventional Imaging, 2021, 102, 199-211.	1.8	10
21	Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.. Journal of Clinical Oncology, 2021, 39, 9015-9015.	0.8	8
22	Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. European Journal of Cancer, 2021, 151, 252-253.	1.3	1
23	Heterogeneity of treatment effects in malignant pleural mesothelioma â€“ Authors' reply. Lancet, The, 2021, 398, 302.	6.3	2
24	Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway. Lung Cancer, 2021, 160, 28-31.	0.9	7
25	Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial. Lung Cancer, 2021, 164, 84-90.	0.9	0
26	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Nonâ€“Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. JCO Precision Oncology, 2020, 4, 829-840.	1.5	25
27	Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer, 2020, 20, 1186.	1.1	8
28	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). European Journal of Cancer, 2020, 141, 62-81.	1.3	122
29	Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989985.	1.4	42
30	Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous nonâ€“small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. European Journal of Cancer, 2020, 131, 27-36.	1.3	44
31	NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology, 2020, 15, 1147-1159.	0.5	88
32	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. PLoS ONE, 2020, 15, e0243961.	1.1	15
33	Title is missing!. , 2020, 15, e0243961.		0
34	Title is missing!. , 2020, 15, e0243961.		0
35	Title is missing!. , 2020, 15, e0243961.		0
36	Title is missing!. , 2020, 15, e0243961.		0

#	Article	IF	Citations
37	<scp>STK</scp> 38 kinase acts as <scp>XPO</scp> 1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes. EMBO Reports, 2019, 20, e48150.	2.0	34
38	Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Nonâ€“small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2). Clinical Lung Cancer, 2019, 20, 222-230.	1.1	3
39	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. Clinical Cancer Research, 2019, 25, 5759-5765.	3.2	13
40	Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Members Reveals Specific Alteration Pattern in Diffuse Gliomas. Journal of Molecular Diagnostics, 2019, 21, 695-704.	1.2	11
41	Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. Clinical Lung Cancer, 2019, 20, e564-e575.	1.1	49
42	Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Lung Cancer, 2019, 132, 65-71.	0.9	120
43	NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 158.	3.5	22
44	MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. British Journal of Cancer, 2019, 120, 387-397.	2.9	19
45	RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome. Journal of Thoracic Oncology, 2019, 14, e250-e251.	0.5	1
46	RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasisâ€”an updated review. Cell Death and Disease, 2019, 10, 928.	2.7	51
47	Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial. Cancers, 2019, 11, 1835.	1.7	4
48	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncology, The, 2019, 20, 239-253.	5.1	342
49	Immunotherapy in relapsed mesothelioma. Immunotherapy, 2018, 10, 77-80.	1.0	5
50	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. Lung Cancer, 2018, 123, 14-21.	0.9	21
51	Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. European Respiratory Journal, 2018, 51, 1701467.	3.1	16
52	Gut microbiome influences efficacy of PD-1â€“based immunotherapy against epithelial tumors. Science, 2018, 359, 91-97.	6.0	3,689
53	Lazarus Syndrome With Crizotinib in a Nonâ€“Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation. Clinical Lung Cancer, 2018, 19, e57-e61.	1.1	5
54	A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control. Cell Communication and Signaling, 2018, 16, 66.	2.7	28

#	Article	IF	Citations
55	Hyperprogressive Disease in Patients With Advanced Nonâ€“Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncology, 2018, 4, 1543.	3.4	567
56	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer, 2017, 116, 1505-1512.	2.9	25
57	Bevacizumab in advanced lung cancer: state of the art. Future Oncology, 2017, 13, 2515-2535.	1.1	53
58	A review of bevacizumab in the treatment of malignant pleural mesothelioma. Future Oncology, 2017, 13, 2537-2546.	1.1	14
59	Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment. European Respiratory Journal, 2017, 50, 1700310.	3.1	21
60	Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. Respiratory Research, 2017, 18, 120.	1.4	41
61	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of Clinical Oncology, 2017, 35, 1403-1410.	0.8	277
62	MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial. Oncotarget, 2017, 8, 4313-4329.	0.8	16
63	Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. European Respiratory Journal, 2016, 48, 861-872.	3.1	17
64	Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?. European Respiratory Journal, 2016, 47, 1890-1891.	3.1	1
65	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet, The, 2016, 387, 1415-1426.	6.3	790
66	RASSF1A Suppresses the Invasion and Metastatic Potential of Human Nonâ€“Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway. Cancer Research, 2016, 76, 1627-1640.	0.4	92
67	ROS-1 rearrangements in non-small cell lung cancer (NSCLC): a new target for a small subset of patients but a giant leap in therapeutics. Current Pulmonology Reports, 2016, 5, 57-62.	0.5	1
68	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet, The, 2016, 387, 1405-1414.	6.3	753
69	Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. European Journal of Cancer, 2016, 52, 120-128.	1.3	42
70	Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. Journal of Thoracic Oncology, 2015, 10, 1451-1457.	0.5	141
71	Do atmospheric conditions influence the first episode of primary spontaneous pneumothorax?. Interactive Cardiovascular and Thoracic Surgery, 2015, 21, 296-300.	0.5	13
72	ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?. Expert Review of Anticancer Therapy, 2015, 15, 225-233.	1.1	9

#	Article	IF	Citations
73	BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. European Respiratory Journal, 2015, 45, 1403-1414.	3.1	66
74	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 257-265.	5.1	1,269
75	Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). Lung Cancer, 2015, 89, 139-145.	0.9	10
76	No impact of passive smoke on the somatic profile of lung cancers in never-smokers. European Respiratory Journal, 2015, 45, 1415-1425.	3.1	27
77	Randomized phase IIâ€“III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. Annals of Oncology, 2015, 26, 908-914.	0.6	81
78	Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. Journal of Clinical Oncology, 2015, 33, 992-999.	0.8	326
79	Erlotinibversuscarboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504. European Respiratory Journal, 2015, 46, 1440-1450.	3.1	7
80	Postoperative Radiotherapy for Pathologic N2 Nonâ€“Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence. Journal of Clinical Oncology, 2015, 33, 2930-2931.	0.8	15
81	SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nature Genetics, 2015, 47, 1200-1205.	9.4	252
82	First-in-human phase I administration of YS110, a monoclonal antibody directed against the CD26 immunostimulatory molecule in advanced cancer patients.. Journal of Clinical Oncology, 2015, 33, 2519-2519.	0.8	0
83	Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1266-1267.	0.4	17
84	Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatinâ€“gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. BMC Cancer, 2014, 14, 953.	1.1	12
85	Reply to letter. European Journal of Cancer, 2014, 50, 678.	1.3	0
86	A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. Annals of Oncology, 2014, 25, 2156-2162.	0.6	26
87	Retrospective observational study of diagnostic accuracy of the XpertÂ® MTB/RIF assay on fiberoptic bronchoscopy sampling for early diagnosis of smear-negative or sputum-scarce patients with suspected tuberculosis. BMC Pulmonary Medicine, 2014, 14, 137.	0.8	45
88	Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Annals of Oncology, 2014, 25, 126-131.	0.6	270
89	A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Nonâ€“Small Cell Lung Cancer Settingâ€”IFCT/ERMETIC2 Project Part 1. Journal of Molecular Diagnostics, 2014, 16, 45-55.	1.2	31
90	Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002. Clinical Cancer Research, 2014, 20, 4613-4624.	3.2	195

#	Article	IF	Citations
91	A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. BMC Cancer, 2014, 14, 231.	1.1	19
92	Customized Adjuvant Phase II Trial in Patients With Nonâ€“Small-Cell Lung Cancer: IFCT-0801 TASTE. Journal of Clinical Oncology, 2014, 32, 1256-1261.	0.8	66
93	Second-line therapy in elderly patients with advanced nonsmall cell lung cancer. European Respiratory Journal, 2014, 43, 240-249.	3.1	10
94	Abstract CT209: A phase I study with the oral pan-CDK inhibitor BAY 1000394 in patients with advanced stage small cell lung or ovarian cancer. , 2014, , .		1
95	Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience.. Journal of Clinical Oncology, 2014, 32, 11035-11035.	0.8	4
96	Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial.. Journal of Clinical Oncology, 2014, 32, 7505-7505.	0.8	1
97	National multidisciplinary tumor board (MTB): Report of the first 526 questions raised within RYTHMIC, the network for thymic malignancies in France.. Journal of Clinical Oncology, 2014, 32, 7605-7605.	0.8	0
98	Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial.. Journal of Clinical Oncology, 2014, 32, 7511-7511.	0.8	0
99	Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. BMC Infectious Diseases, 2013, 13, 435.	1.3	11
100	A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial). European Journal of Cancer, 2013, 49, 2654-2664.	1.3	47
101	Does Bilobectomy Offer Satisfactory Long-Term Survival Outcome for Non-Small Cell Lung Cancer?. Annals of Thoracic Surgery, 2013, 95, 1726-1733.	0.7	6
102	Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. European Respiratory Review, 2013, 22, 565-576.	3.0	23
103	From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue franÃ§aise (GOLF). Annals of Oncology, 2013, 24, 586-597.	0.6	88
104	In vivoprobe-based confocal laser endomicroscopy in amiodarone-related pneumonia. European Respiratory Journal, 2013, 42, 1646-1658.	3.1	38
105	Topics in thoracic oncology: from surgical resection to molecular dissection. European Respiratory Review, 2013, 22, 101-102.	3.0	3
106	Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study. Journal of Thoracic Oncology, 2013, 8, 906-914.	0.5	12
107	Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).. Journal of Clinical Oncology, 2013, 31, 8000-8000.	0.8	70
108	An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial. Clinical Cancer Research, 2012, 18, 2976-2986.	3.2	52

#	Article	IF	Citations
109	Impact of Point Spread Function Reconstruction on Thoracic Lymph Node Staging With 18F-FDG PET/CT in Nonâ€“Small Cell Lung Cancer. Clinical Nuclear Medicine, 2012, 37, 971-976.	0.7	53
110	Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group. Journal of Thoracic Oncology, 2012, 7, 599-606.	0.5	43
111	Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Nonâ€“Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials. Journal of Thoracic Oncology, 2012, 7, 841-849.	0.5	104
112	Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Nonâ€“Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Projectâ€”Part 2). Journal of Thoracic Oncology, 2012, 7, 1490-1502.	0.5	69
113	High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Nonâ€“Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway. Molecular Cancer Therapeutics, 2012, 11, 1203-1213.	1.9	77
114	A STEPP too far for FLEX?. Lancet Oncology, The, 2012, 13, e51.	5.1	1
115	Lung cancer in never smokers â€“ A review. European Journal of Cancer, 2012, 48, 1299-1311.	1.3	694
116	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3516-3524.	0.8	214
117	Observational Study of QuantiFERONÂ®-TB Gold In-Tube Assay in Tuberculosis Contacts in a Low Incidence Area. PLoS ONE, 2012, 7, e43520.	1.1	17
118	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation, 2012, 125, 2128-2137.	1.6	548
119	Prognostic value of pathologic complete response to preoperative chemotherapy in early-stage non small cell lung cancer: Combined analysis of two IFCT randomized trials.. Journal of Clinical Oncology, 2012, 30, 7057-7057.	0.8	0
120	Myocardial Strain Assessment in Cystic Fibrosis. Journal of the American Society of Echocardiography, 2011, 24, 1037-1045.	1.2	24
121	Chemotherapy in elderly patients with advanced non-small cell lung cancer. Lung Cancer, 2011, 74, 364-368.	0.9	24
122	Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet, The, 2011, 378, 1079-1088.	6.3	521
123	Evaluation of current practice. Anti-Cancer Drugs, 2011, 22, 919-925.	0.7	15
124	Pulmonary Hypertension in Patients With Neurofibromatosis Type I. Medicine (United States), 2011, 90, 201-211.	0.4	60
125	Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in) Tj ETQq1 1 0.784314 rgBT /Overlock 1006-1015.	3.4	82
126	Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. European Respiratory Journal, 2011, 37, 183-193.	3.1	37

#	Article	IF	Citations
127	Admission of advanced lung cancer patients to intensive care unit: A retrospective study of 76 patients. BMC Cancer, 2011, 11, 159.	1.1	58
128	Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer. Current Opinion in Oncology, 2011, 23, 106-111.	1.1	12
129	Osteoblastic Reaction in Non-small Cell Lung Carcinoma and its Association to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Response and Prolonged Survival. Journal of Thoracic Oncology, 2010, 5, 491-496.	0.5	51
130	Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer, 2010, 70, 301-307.	0.9	40
131	La recherche clinique en cancÃ©rologie thoracique: place et rÃ1e de lâ€™Intergroupe francophone de cancÃ©rologie thoracique (IFCT). Oncologie, 2009, 11, 343-347.	0.2	0
132	Gefitinib plus docetaxel in non-small-cell lung cancer. Lancet, The, 2009, 373, 541.	6.3	3
133	Prise en charge diagnostique et thÃ©rapeutique du mÃ©sothÃ©liome pleural malin en 2008. Oncologie, 2008, 10, 545-550.	0.2	1
134	Breathingâ€“Swallowing Interaction in Neuromuscular Patients. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 269-276.	2.5	76
135	Long-term results of endobronchial brachytherapy: A curative treatment?. International Journal of Radiation Oncology Biology Physics, 2007, 67, 425-430.	0.4	56
136	Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1026-1032.	3.3	42
137	Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2004, 350, 351-360.	13.9	2,161
138	Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy fornon-small-cell lung cancer. Annals of Oncology, 2004, 15, 38-44.	0.6	36
139	Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and A Universal Oligonucleotide Array. Clinical Cancer Research, 2004, 10, 3479-3489.	3.2	277
140	RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Experimental Cell Research, 2003, 291, 363-376.	1.2	94
141	Detection of p73 antibodies in patients with various types of cancer: immunological characterization. British Journal of Cancer, 2001, 84, 57-63.	2.9	19
142	Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. International Journal of Cancer, 2000, 89, 81-86.	2.3	40
143	A Misleading Pulmonary Lesion in a Patient with Acute Monoblastic Leukemia. Leukemia and Lymphoma, 2000, 37, 457-459.	0.6	0
144	Interaction of the Grb7 adapter protein with Rnd1, a new member of the Rho family. FEBS Letters, 2000, 467, 91-96.	1.3	24

#	ARTICLE	IF	CITATIONS
145	Quantitative Fluorescence in Situ Hybridization in Lung Cancer as a Diagnostic Marker. Journal of Molecular Diagnostics, 1999, 1, 33-37.	1.2	8
146	RhoGAPs and RhoGDIs, (His)stories of Two Families. Progress in Molecular and Subcellular Biology, 1999, 22, 85-113.	0.9	33
147	The p53 Tumor Suppressor Gene in Lung Cancer: From Molecular to Serological Diagnosis. , 1998, , 221-230.		0
148	Fluoxetin-induced pulmonary granulomatosis. European Respiratory Journal, 1996, 9, 615-617.	3.1	23
149	RhoGDI-3 Is a New GDP Dissociation Inhibitor (GDI). Journal of Biological Chemistry, 1996, 271, 30366-30374.	1.6	107
150	Serum p53 antibodies as early markers of lung cancer. Nature Medicine, 1995, 1, 701-702.	15.2	293
151	Prolonged Survival After High-Dose Rate Endobronchial Radiation for Malignant Airway Obstruction. Chest, 1994, 105, 767-772.	0.4	93
152	Detection and Sequencing of p53 Gene Mutations in Bronchial Biopsy Samples in Patients With Lung Cancer. Chest, 1994, 106, 1309-1310.	0.4	0
153	Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. British Journal of Cancer, 1994, 69, 809-816.	2.9	141